Boston Biomedical, the developers of next generation cancer therapeutics, is resolute in delivering within three years the world’s first–ever cancer stem cell agent to help battle the life-threatening illness.
Located in Cambridge, Massachusetts, Boston Biomedical was by Dr. Chiang Li in 2006 and was acquired by Sumitomo Dainippon Pharma for nearly US$ 2.6 billion in 2012.
“Since the acquisition, Boston Biomedical has grown both in high-count space by about 600%. We’re very well positioned. We have built a great database for our products and our clinical trial program has grown manifold globally,” said Chiang, who has remained CEO of the biotechnology company.
Boston Biomedical has gone on to expand its clinical development programs, R&D activities, and commercial opportunities.
For its pioneering work, Boston Biomedical received the National Cancer Institute’s Cancer Stem Cells Initiative Award in 2009, took one of the World’s Top Ten Cancer Drugs in Late Stage Clinical Development in 2012, and named “Company to Watch” at the 10th Annual Team Massachusetts Economic Impact Awards in 2013.
“In the East Coast, we have certainly developed one of the best ecosystems for healthcare innovation. We have clinical medical delivery. As a physician, scientist and entrepreneur, we are very privileged to be in Boston and be able to see the problem that patients are facing,” said Li.
A fully integrated oncology drug research and development company with many scientists renowned in their respective fields, Boston Biomedical boasts several compounds, including peptide vaccines and immune response modifiers, in early stage development.